Abstract:The purinergic receptor P2Y12 (P2Y12R) is a well-recognized target for anti-thrombotic agents. This receptor is also expressed in microglia, where it plays a key role in neuroinflammation and microglia activation. To investigate P2Y12R-mediated actions in the central nervous system (CNS), the development of novel brain-penetrant ligands is essential, along with further in vitro studies. A radiolabeled, easily accessible tool compound would significantly advance such drug discovery efforts. Herein, we describe the 3H-labeling of a non-nucleotide P2Y12R antagonist AZ12464237, and its in vitro binding properties to the receptor in membrane preparations form transfected cells, as well as on mouse brain tissues. The radioligand shows high affinity toward both the human and rat P2Y12R in transfected cells, with Kd values of 3.12 nM (human) and 16.6 nM (rat), as determined by saturation binding studies. The binding kinetics of [3H]AZ12464237 are rapid with a short target residence time (~1 min). We further confirmed the selectivity of the radioligand by performing competitive displacement studies, in which reported P2Y12R ligands and other P2Y receptors ligands were tested for binding against [3H]AZ12464237. Additionally, the radioligand proved useful for in vitro autoradiography studies on mouse brain tissues, although a small amount of off-target binding was observed in P2Y12R knock-out mice. This could be traced to glycogen synthase kinase 3 α. Considering the growing interest in P2Y12R as a biomarker for microglia activation, [3H]AZ12464237 represents a promising tool for in vitro studies, including screening assays aimed at identifying novel P2Y12R ligands for CNS applications.

Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy

Synthesis and Structure–Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

A Second Drug Binding Site in P2X3

Druggable negative allosteric site of P2X3 receptors

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

P2X7 receptors exhibit at least three modes of allosteric antagonism

Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist

Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.

Discovery of (S)–N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl)pyrrolidine-1-carboxamide as potent and brain-penetrant TRPV1 antagonist

[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors

Design, Synthesis and Anti-Inflammatory Evaluation of 3-Amide Benzoic Acid Derivatives As Novel P2Y14 Receptor Antagonists.

Naphtho[1,2-b][1,4]diazepinedione-based P2X4 Receptor Antagonists from Structure-Activity Relationships Study Towards PET Tracer Development

Characterization of [3H]AZ12464237 as a high affinity, non-nucleotide antagonist radioligand for the P2Y12 receptor

Pyrazolopyrimidines As Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels.

Discovery of a Potent (4R,5S)-4-Fluoro-5-Methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonist and its Methylene Phosphate Prodrug Guided By Molecular Modeling.

Structural Insights into the Allosteric Inhibition of P2X4 Receptors

Discovery of (S)-3-(4-(benzyloxy)phenyl)-2-(2-phenoxyacetamido)propanoic Acid Derivatives As a New Class of GPR34 Antagonists.

Dyclonine Inhibition of TRPV3: from Functional Discovery to Structural Insight

Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists

Design, Synthesis and Biological Evaluation of Novel 2,3,4,9-Tetrahydro-1h-pyrido[3,4-b]indole Triazole Derivatives As Potent TRPV1 Antagonists.